Patentable pharmahuasca “kits of parts”?

New PCT app published: “Compositions & Kits of Parts Comprising N,N-DMT & Harmine & Their Use in Therapy”

“An alternative to ayahuasca that solves the problems of side effects…is pharmahuasca, also known as synthetic ayahuasca”

1/4
Applicant is University of Zürich, w inventors Dario Dornbierer, Davor Kosanic, & Milan Scheidegger

All are founders at Reconnect Labs: “a Spin-off of the University of Zürich…setting standards for a novel kind of ethical drug development company”

reconnect-foundation.org/reconnect-labs/

2/4
The PCT app claims:

–a “kit of parts” of DMT & harmine

–a composition of DMT & harmine

-their use to treat psychiatric disorders

None were found inventive

3/4
PCT application: patentscope.wipo.int/search/en/deta…

Written opinion: patentscope.wipo.int/search/docs2/p…

Follow psychedelic patent applications with the @PsilocybinAlpha Patent Trackers:

psilocybinalpha.com/data

4/4

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Graham Pechenik

Graham Pechenik Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @calyxlaw

30 Dec 21
New psychedelic inventions?

∰ Field Trip—tryptamine prodrugs

∰ Greenway DNA—personalized psychedelic treatment

∰ Small Pharma—deuterated DMT

1/9
Field Trip $FTRP: “Tryptamine Prodrugs”

Application covers diacid hemiester prodrugs of tryptamines & isotryptamines, eg, psilocin, 4-HO-DET, 4-HO-DiPT, & 4-HO-MiPT

Head twitch response & pharmacokinetics in rats & humans with 4-hemiglutarate & 4-hemisuccinate of 4-HO-DiPT

2/9
Is Field Trip $FTRP FT-104 a prodrug of 4-HO-DiPT?

In “Use in Treatment,” app discloses intramuscular & subcutaneous injection or oral tablet administration of:

N,N-isopropyltryptamine-4-glutarate (4-hemiglutarate of 4-HO-DiPT)

& subcutaneous “injectable formulation kit”

3/9
Read 9 tweets
29 Dec 21
New psychedelic inventions?

⁂ Phil Wolfson/KRF—ketamine for postpartum symptoms

⁂ Psilo Scientific—psychoactive & psychedelic fungus extraction

⁂ Cognigenics—5-HT2A “cognitive upgrade”

⁂ Liechti—MDMA response prediction

⁂ Small Pharma—DMT-type compound synthesis

1/14
…and more new psychedelic inventions?

⁂ Ixtlan—psilocybin for Alzheimer’s

⁂ Spirify—hydroxynorketamine analogs

⁂ Guangzhou Dazhou Biomedicine—transdermal ketamine

⁂ Disruption Labs—nanoparticle compositions

⁂ Daniel Lilly—“medicinal food products” with psilocybin

2/14
Ketamine Research Foundation (KRF)—“Ketamine for the Treatment of Postpartum Symptoms & Disorder”

First inventor Phil Wolfson

“treatment of all forms of emotional and psychological symptoms and disorders related to childbirth and its aftermath”

patentscope.wipo.int/search/en/deta…

3/14
Read 14 tweets
20 Nov 21
Novel ketamine + psilocybin inventions?

New patent applications published:

𝔎 Celon Pharma—pulmonary administration of ketamine

𝔎 Univ Kansas—ketamine treatment for ALS

𝔎 Takeda Pharm—depression tx, after ketamine therapy

𝔎 CaaMTech—combinations of serotonergic drugs

1/6
Celon Pharma—“Ketamine Composition for Use in a Method of Treatment of Depression by Pulmonary Administration”

–inhalable dry powder ketamine compositions

–dosage regimens for their use “in a cycle of administrations of sequences of single doses”

appft.uspto.gov/netacgi/nph-Pa…

2/6
University of Kansas—“Ketamine Treatment for Amyotrophic Lateral Sclerosis”

Covers use of ketamine to:

–extend life expectancy

–increase number of days of survival

–reduce rate of deterioration of body weight

Claims all found novel & inventive

patentscope.wipo.int/search/en/deta…

3/6
Read 6 tweets
18 Nov 21
Ibogaine + MDA = “an extremely beneficial drug”?

#TBT to 1968 patents by Claudio Naranjo

“The medical preparation of the invention produces most unexpected and beneficial results, by for example alleviating fears and anxieties which may have been present in the patient”

1/12 Image
The patents claimed medical preparations of:

(1) ibogaine, iboga alkaloid extract, or total extract; plus

(2) amphetamine, MDA, TMA, tetrahydronapthylamine, or naphazoline

“The best results have been obtained with” MDA

The combination “forms an excellent medicine"

2/12 ImageImage
The ibogaine “has the effect of considerably clarifying the mind of the sick person, giving him a kind of extra-lucid vision of his ‘ego.’ It likewise excites the memory centre of the brain thus revealing memories which may go back to a period before the age of 4…”

3/12 Image
Read 12 tweets
21 Mar 21
New Compass Pathways patents granted?

Another US patent was granted on March 16, 2021

This is Compass’ second US patent, in same family as the first patent granted on December 31, 2019

New ‘257 patent: patft.uspto.gov/netacgi/nph-Pa…

First ‘175 patent: patft.uspto.gov/netacgi/nph-Pa…

1/7
A primary difference between the new ‘257 & the first ‘175 patent is:

– ‘175 patent claims methods “of treating drug resistant depression” by orally administering “an oral dosage form“ of the COMP360 psilocybin Polymorph A

– ‘257 patent claims the “oral dosage form” itself

2/7
Just as with the first ‘175 patent, the new ‘257 patent claims the psilocybin Polymorph A by reference to its “XRPD diffractogram”

These are the peaks displayed when the polymorph is analyzed by X-ray

Compass unsuccessfully sought claims without these XRPD limitations

3/7
Read 7 tweets
20 Mar 21
Who will own psilocybin for anorexia?

One of the methods claimed in Compass’ PCT application is administering “a therapeutically-effective dose of psilocybin” to a subject with anorexia

Could a claim on treating anorexia with psilocybin be granted?

1/7
Compass is listed as collaborator on an investigator-initiated study at UC San Diego, to explore the safety, tolerability, & efficacy of psilocybin-assisted therapy for anorexia

This trial was first posted on December 10, 2020

2/7

clinicaltrials.gov/ct2/show/NCT04…
Another study, sponsored by Imperial College London, will also assess the acceptability & efficacy of treating anorexia with psilocybin, & will use MRI & EEG to examine neuronal underpinnings of tx

This trial was posted earlier, on August 10, 2020

3/7

clinicaltrials.gov/ct2/show/NCT04…
Read 7 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us on Twitter!

:(